Cancer Care Ontario | Action Cancer Ontario

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

980 Results

Regimen

TRIFTIPI

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

trifluridine / tipiracil

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2022

Regimen

LURB

Cancer Type:

Lung,

Small Cell

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

lurbinectedin (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

CISPPEME

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal)

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

pemetrexed,

CISplatin

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Dec 1969

Regimen

CLAD

Cancer Type:

Hematologic,

Rare Diseases

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

cladribine

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Jul 2021

Regimen

CRBPPACL+PEMB

Cancer Type:

Head and Neck,

Squamous Cell

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen